Top news of the week: 27.10.2020.
#IPOs #database #biotech #Covid19 #lifescience #SeeYourselfinSTEM
Startups
RT @FierceBiotech: “What a scorpion does is sting, and it does so precisely. We are a precision oncology company that would like to put the sting in cancer,” Glick, Scorpion’s president and CEO, said. https://t.co/XMhKTWvDPe
OpenScorpion Therapeutics debuts with $108M to 'put the sting in cancer'
When Gary Glick, Ph.D., left the CEO post at IFM Therapeutics, he didn’t know what was next. But he soon found himself on a plane with Loxo Oncology co-founder Keith Flaherty, and they ...
.@BioPharmaDive's #database will help you take stock of #biotech's biggest #IPOs from the recent past:
https://t.co/DafgdJ0RD6
OpenA record number of biotechs are going public. Here's how they're performing.
Initial public offerings have fueled biotech's boom. A new database built by BioPharma Dive will help you keep track of them as they happen.
Democrats want to fire Warp Speed’s Moncef Slaoui and overhaul the #Covid19 vaccine and drug program. But if Biden wins, should he? https://t.co/BKC1s7U5Rl via @NicholasFlorko https://t.co/2trcvYCUGK
OpenDemocrats want to fire Warp Speed’s Moncef Slaoui and overhaul the program. But if Biden wins, should he?
Democrats have called for the ouster of the Warp Speed chief and an overhaul of the program. But if Biden wins, should he upend it?
U.S. biotechnology startups raised $19.5 billion through Sept. 30, more than in all of last year, industry data shows
https://t.co/gB9xoJ0Dlv
OpenInvestors Pump Billions into Biotech Startups, Pay Skyrocketing Prices
U.S. biotechs rounded up $19.5 billion in venture capital through Sept. 30, topping the $17.4 billion they raised for all of 2019. ‘We’re in a golden age of biotech,’ says one venture ...
Be Biopharma debuts with $52M to advance engineered B-cell therapies https://t.co/F4TGwWiZDc https://t.co/46VwctXHPt
OpenBe Biopharma debuts with $52M to advance engineered B-cell therapies
You may have heard of T cells before, but Aleks Radovic-Moreno, Be Biopharma’s co-founder, president and director, is betting on B cells as the future of cell therapies.
Foghorn Therapeutics raises $120 million in IPO
The biotech company is working on a system to regulate genes to treat cancer.
Never before have so many companies with no revenue pursued a public listing at such high valuations https://t.co/NJJIatKiV3
OpenElectric-Vehicle Startups Are Wall Street’s Hot New Thing. No Revenue? No Problem.
A frenzy has hit the electric-vehicle sector. Buoyed by the surge in the stock price of Tesla and a rush of blank-check companies that take startups public, investors are hoping to find the ...
RT @LS_Cares: . @ProjectOnramp, created in partnership w/ @MassBio, @MassBioEd, @LS_Cares & @MALifeSciences, works to help students start their careers in the #lifescience industry by matching them w/internships. Together, let's create opportunities! #SeeYourselfinSTEM https://t.co/0I36XtBhSZ https://t.co/CYbnJgeGpT
OpenProject Onramp
Join Life Science Cares, MassBio, MassBioEd, and the Mass Life Science Center as we commit to source 50 industry internships for Bottom Line Students this summer in Project …